<DOC>
	<DOCNO>NCT01051518</DOCNO>
	<brief_summary>The investigation concern prospective , multicenter , single arm safety performance study evaluate Medtronic CoreValve system . Approximately 120 patient present symptomatic aortic native valve stenosis necessitate valve replacement consider poor surgical candidate , high surgical risk , attest surgeon cardiologist recruit study . Safety performance evaluate discharge 30 day post-procedure . Valve performance placement follow 3 6 month post-procedure . Further long-term patient follow-up visit perform 12 , 24 , 36 48 month post-procedure .</brief_summary>
	<brief_title>Clinical Evaluation Percutaneous Implantation Medtronic CoreValve Aortic Valve Prosthesis ( 18Fr-Study )</brief_title>
	<detailed_description />
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<criteria>Native aortic valve disease , define valve stenosis aortic valve area &lt; 1cm² ( &lt; 0.6cm2/m2 ) determine echocardiographic measure , ≥ 75 year , Surgical risk calculate logistic EuroSCORE ≥ 15 % , One two ( 2 ) follow complicate factor : 1 . Cirrhosis liver ( Child class A B ) , 2 . Pulmonary insufficiency : Forced expiratory volume one second ( FEV1 ) &lt; 1 liter , 3 . Previous cardiac surgery ( Coronary artery bypass grafting ( CABG ) , valvular surgery ) , 4 . Pulmonary hypertension &gt; 60 mmHg high risk cardiac surgery valve replacement , 5 . Porcelain aorta 6 . Recurrent pulmonary embolus , 7 . Right ventricular insufficiency , 8 . Thoracic burn sequela contraindicate open chest surgery , 9 . History mediastinum radiotherapy , 10 . Severe connective tissue disease result contraindication surgery , 11 . Cachexia ( BMI ≤ 18 kg/m² ) , Aortic valve annulus diameter ≥ 20 mm ≤ 27 mm determine echocardiographic measure , Ascending aorta diameter £ 45 mm sinotubular junction , Signed Informed Consent . Known hypersensitivity contraindication aspirin , heparin , ticlopidine , clopidogrel , Nitinol , sensitivity contrast medium adequately premedicated , Any sepsis , include active endocarditis , Recent myocardial infarction ( &lt; 30 day ) , Percutaneous coronary vascular intervention within 15 day prior study procedure , schedule within 30 day study procedure , Any leave ventricular atrial thrombus diagnose echocardiography , Uncontrolled atrial fibrillation ( heart rate great 100 bpm ) , Mitral tricuspid valvular insufficiency ( &gt; grade II ) , Previous aortic valve replacement ( mechanical valve OR stented bioprosthetic valve ) , Any condition consider contraindication extracorporeal assistance , Evolutive recent CVA ( cerebro vascular accident ) , Poly arterial patient either : 1 . Femoral , iliac aortic vascular condition ( e.g . stenosis , tortuosity ) , make insertion endovascular access aortic valve impossible , 2 . Symptomatic carotid vertebral artery narrow ( &gt; 70 % ) disease , 3 . Abdominal thoracic aortic aneurysm , Bleeding diathesis coagulopathy , patient refuse blood transfusion , Evolutive disease life expectancy le one year , Creatinine clearance &lt; 20 ml/min , Pregnancy , Enrolled another investigational study .</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>